Jefferies Financial Group Inc. Decreases Position in Kenvue Inc. $KVUE

Jefferies Financial Group Inc. trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 25.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 55,241 shares of the company’s stock after selling 18,865 shares during the period. Jefferies Financial Group Inc.’s holdings in Kenvue were worth $1,156,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of KVUE. Trust Co. of Vermont boosted its holdings in Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after acquiring an additional 1,150 shares during the period. Truvestments Capital LLC bought a new stake in Kenvue in the first quarter valued at approximately $37,000. Clal Insurance Enterprises Holdings Ltd lifted its position in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares during the last quarter. First Pacific Financial purchased a new stake in shares of Kenvue during the second quarter valued at approximately $54,000. Finally, Ransom Advisory Ltd bought a new position in shares of Kenvue in the first quarter worth approximately $56,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $17.22 on Thursday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The stock has a market capitalization of $32.98 billion, a P/E ratio of 22.95 and a beta of 0.71. The company’s 50-day moving average is $16.10 and its 200 day moving average is $19.65. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same period in the previous year, the firm posted $0.28 EPS. The business’s revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. Kenvue’s payout ratio is currently 110.67%.

Analyst Ratings Changes

A number of equities research analysts recently commented on KVUE shares. Deutsche Bank Aktiengesellschaft set a $18.00 price target on shares of Kenvue in a report on Friday, October 24th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Barclays boosted their price target on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Finally, Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.